Erlotinib and nonsmall cell lung cancer with brain metastases: A case study with a complete and prolonged response over 17 months;Erlotinib et métastases cérébrales d'un cancer bronchique non à petites cellules : une réponse complète et prolongée de 17 mois

Revue de Pneumologie Clinique

Volumn 65, Issue 5, 2009, Pages 318-321

  Mairovitz, A ^a   Staub, E ^a   Le Floch, H ^a   Riviere F ^a   Bonnichon, A ^a   Margery, J ^a   Vaylet, F ^a  

^a Service de pneumologie   (France)

Author keywords

Brain metastases; Erlotinib; Nonsmall cell lung cancer

Indexed keywords

CARBOPLATIN; ERLOTINIB; GEMCITABINE; PACLITAXEL;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CASE REPORT; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 70350344096     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneumo.2009.06.002     Document Type: Article

References (17)

1. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
2. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall cell lung cancer previously treated with platinium-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
4. Vansteenkiste J. Improving patient management in metastatic non-small cell lung cancer. Lung Cancer 57 Suppl. 2 (2007) S12-S17
5. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previuosly treated non-small cell lung cancer. N Engl J Med 353 2 (2005) 123-132
6. Bréchot J.M. Place des thérapeutiques ciblées : les inhibiteurs des tyrosines kinases. Rev Pneum Clin 60 5 (2004) 3S68-3S71
7. Thatcher N. Integrating new targeted agents into the treatment of non-small-cell lung cancer. Lung Cancer 54S (2006) S25-S31
8. Popat S., Hughes S., Papadopoulos P., Wilkins A., Moore S., Priest K., et al. Recurrent responses to non-small cell lung cancer brain metastasis with erlotinib. Lung Cancer 56 (2007) 125-137
9. Gounant V., Wislez M., and Poulot V. Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer 58 (2007) 425-428
10. Pan M., Santamaria M., and Wollman D.B. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat Pract Oncol 4 10 (2007) 603-607
11. Lai C.S.L., Boshoff C., Falzon M., and Lee S.M. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 61 1 (2006) 91
12. Langer C.J., and Mehta M.P. Current management of brain metastasis, with a focus on systemic options. J Clin Oncol 23 26 (2005) 6207-6219
13. Ceresoli G.L., Cappuzzo F., Gregorc V., Bartolini S., Crinò L., and Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15 7 (2004) 1042-1047
14. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 22 (2004) 5235-5246
15. Huang Y.-J., et al. Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer. Lung Cancer (2007) 10.1016/j.lungcan.2007.07.015
16. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009 [Epub ahead of print].
17. Bezjak A., Seymour L., Clark G., Trajkovic A., Zukin M., Ayoub J., et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical trials Group BR21. J Clin Oncol 24 24 (2006) 3S31-3S37